canarypox-hil-12 melanoma vaccine
Vaccineexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 1999 (NCT00003556)
Timeline
1990s
- Jan 1, 1999
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Melanoma cellsImmunity, active
immunity, active - melanoma cells
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- canarypox-hil-12 melanoma vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00003556 | Phase 1 | Jan 1, 1999 | National Cancer Institute (NCI), University of Alabama, Birmingham |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 1999 |
| University of Alabama, Birmingham | Academic/Hospital | 1 | 0 | 1 | 1999 |
2 organizations
Page 1 / 1